Highlights

  • Ansell (ASX:ANN) shares were trading at A$42.16, down 0.17% at the time of writing on 9 September 2026.
  • The stock’s modest decline came while the S&P/ASX 200 Health Care index was down 1.69%.
  • Ansell reported FY26 sales of US$2.14 billion and adjusted EBIT of US$321.9 million.
  • FY27 adjusted EPS is expected to range between US158 cents and US170 cents, supported by sales growth and productivity initiatives.

Ansell Limited (ASX:ANN) shares were trading marginally lower on Wednesday, with the stock changing hands at A$42.16, down 0.17% at the time of writing on 9 September 2026.

The broader Australian Equity market was also softer. The S&P/ASX 200 (ASX:XJO) was trading at 8,896.00 points, down 0.28% at the time of writing on 9 September 2026, while the S&P/ASX 300 (ASX:XKO) stood at 8,824.90 points, down 0.31%.

Healthcare equities were under considerably greater pressure, with the S&P/ASX 200 Health Care (ASX:XHJ) trading at 31,299.70 points, down 1.69% at the time of writing on 9 September 2026.

Ansell’s decline was therefore relatively modest compared with the broader healthcare sector. With no specific catalyst established for Wednesday’s trading, the share-price move should not automatically be linked to the company’s recent financial results or any other corporate event. Short-term movements can reflect normal trading activity, portfolio positioning and changes in sector sentiment without indicating a corresponding shift in underlying fundamentals.

Safety Solutions at Scale

Ansell is a global safety solutions company and integrated manufacturer of personal protective equipment used across healthcare and industrial workplaces.

Its portfolio includes protective gloves, surgical products, cleanroom solutions, chemical-protection equipment and other products designed for workplaces where safety requirements can be demanding. Ansell serves customers across more than 100 countries and operates through two main segments: Healthcare and Industrial.

The Healthcare segment provides products including surgical gloves, examination and single-use gloves, and cleanroom protection. Its customers span hospitals, laboratories, pharmaceutical Manufacturing facilities and other healthcare-related environments.

The Industrial segment provides mechanical and chemical protection products used across manufacturing, aerospace, defence, energy and other specialised workplaces.

This diversified model means Ansell’s performance is influenced by several factors, including industrial activity, hospital and laboratory demand, pricing, raw-material costs, supply-chain efficiency and global trade conditions.

FY26 Delivers Earnings Growth

Ansell released its FY26 full-year results on 24 August 2026, providing investors with a recent detailed view of the company’s operating performance.

The company reported sales of US$2.140 billion, up 6.8% on a reported basis and 5.0% on an organic constant-currency basis.

Adjusted EBIT rose 14.1% to US$321.9 million, while the adjusted EBIT Margin increased by 90 basis points to 15.0%. On an organic constant-currency basis, adjusted EBIT growth was 14.9%.

Adjusted NPAT increased 15.8% to US$212.3 million, while adjusted Earnings Per Share reached US148.6 cents, up 17.8% and landing in the upper half of the company’s guidance range.

Statutory NPAT more than doubled to US$208.6 million, compared with US$101.6 million in FY25. Operating Cash Flow also increased materially to US$270.1 million, representing growth of 156.3%.

The combination of sales growth, margin expansion and improved cash generation provides a broader fundamental backdrop than the company’s small daily share-price movement.

Healthcare and Industrial Mix

Ansell’s two operating divisions made broadly similar contributions to adjusted EBIT during FY26.

The Healthcare segment accounted for 56% of segment sales and 50% of segment adjusted EBIT. Healthcare sales reached US$1.193 billion, representing organic constant-currency growth of 6.4% and reported growth of 8.0%.

Within Healthcare, Exam/Single Use sales increased 5.6% on an adjusted basis, while Surgical sales rose 6.4%. Cleanroom sales increased 10.0%, supported by Demand for clean and sterile products used in pharmaceutical, medical-device and semiconductor production.

Healthcare adjusted EBIT reached US$170.7 million, representing organic constant-currency growth of 23.5%. Management attributed the improvement to higher sales, increased contribution from higher-margin Cleanroom solutions and supply-chain productivity.

The Industrial segment generated US$947.3 million in sales, with organic constant-currency growth of 3.3%. Industrial adjusted EBIT reached US$170.6 million, up 7.9% on an organic constant-currency basis.

These results demonstrate the importance of Ansell’s exposure beyond conventional healthcare, with industrial workplace protection providing another meaningful earnings stream.

Tariffs and Productivity

Global trade and supply-chain conditions remain important issues for Ansell.

The company said its US Business performed well during FY26, with sourcing optimisation and price increases offsetting the effects of higher tariffs. US sales growth accelerated during the second half, supported by industrial and scientific markets.

Ansell also continued to progress its Accelerated Productivity Investment Program. The company said the program had achieved its recurring pre-tax savings target of US$50 million following organisational and manufacturing changes.

Attention is now shifting toward the information technology phase, including ERP system upgrades planned to commence in North America during FY27. Expected total one-off cash costs for the broader program remain between US$85 million and US$90 million.

For investors, productivity initiatives are significant because they can help protect margins against cost Inflation and create additional capacity to invest in higher-growth product categories.

Ansell’s Balance Sheet also improved during FY26. Net Debt to adjusted EBITDA declined to 1.3 times, while the company reported US$752 million of cash and undrawn bank facilities.

FY27 Growth Priorities

Ansell expects further earnings growth in FY27.

The company has guided to adjusted EPS of US158 cents to US170 cents, compared with US148.6 cents in FY26.

Management expects constant-currency sales growth to be supported by higher volumes and pricing actions implemented during FY26. Strategic priorities include the US market, scientific applications and selected industrial segments.

Earnings growth is expected to come from profitable sales growth, commercial initiatives and additional productivity improvements.

Other FY27 assumptions include approximately US$43 million of net interest expense, Capital Expenditure of US$45 million to US$55 million, and approximately US$15 million of one-off pre-tax costs, primarily associated with ERP implementation.

Investors are therefore likely to monitor whether Ansell can convert its FY26 momentum into further growth while navigating uncertain global economic conditions, tariffs and input-cost pressures.

Valuation will also depend on how sustainably the company can expand earnings and margins. A business with diversified end markets and improving productivity can attract investor interest, but expectations around growth, pricing and cost management can influence how the market values future earnings.

Final Takeaway

Ansell (ASX:ANN) shares were trading at A$42.16, down 0.17% at the time of writing on 9 September 2026, compared with a 1.69% decline in the broader S&P/ASX 200 Health Care Index.

The small daily decline should not, by itself, be interpreted as evidence of changing fundamentals.

Ansell’s August FY26 results showed sales of US$2.14 billion, adjusted EBIT of US$321.9 million, adjusted NPAT of US$212.3 million and operating cash flow of US$270.1 million. The company has also guided to higher adjusted EPS in FY27.

For investors, the key issues to watch include healthcare and industrial demand, Tariff management, pricing, Cleanroom growth, productivity initiatives, margin development and execution against the company’s FY27 earnings expectations.